Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen

Precision BioSciences (NASDAQ:DTIL) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

DTIL has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $19.00 target price on shares of Precision BioSciences in a report on Friday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $39.50.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $5.67 on Friday. The stock has a 50-day moving average price of $4.18 and a 200 day moving average price of $4.99. The stock has a market capitalization of $129.84 million, a P/E ratio of -1.11 and a beta of 1.28. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $8.82. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35.

Insider Buying and Selling at Precision BioSciences

In other news, CFO John Alexander Kelly sold 15,213 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $4.03, for a total transaction of $61,308.39. Following the completion of the transaction, the chief financial officer directly owned 106,448 shares in the company, valued at approximately $428,985.44. This represents a 12.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider J. Jefferson Smith sold 10,200 shares of the stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total value of $41,106.00. Following the transaction, the insider owned 110,184 shares of the company’s stock, valued at $444,041.52. This represents a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders bought 7,081 shares of company stock worth $33,714 and sold 93,845 shares worth $376,677. 4.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Precision BioSciences

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its position in Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after purchasing an additional 4,025 shares during the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Precision BioSciences in the 2nd quarter worth $260,000. Corient Private Wealth LLC bought a new stake in shares of Precision BioSciences in the 2nd quarter worth about $425,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Precision BioSciences during the 3rd quarter valued at about $72,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Precision BioSciences by 21.5% in the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock valued at $2,719,000 after acquiring an additional 87,242 shares during the last quarter. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.